List view / Grid view
EMA human medicines committee (CHMP)
Medicines which represented significant progress in their therapeutic areas have been listed in the European Medicines Agency's Human Medicines Highlights 2022 report.
At its latest meeting, EMA’s human medicines committee (CHMP) recommended the approval of four medicines, seven extensions of therapeutic indication and laid out recommendations for diabetes treatment outside of the EU.
The EMA's human medicines committee (CHMP) has recommended a conditional marketing authorisation for Veklury (remdesivir) to treat COVID-19.
The EMA has announced new regulatory changes that will help potential COVID-19 vaccines and therapeutics accelerate through development.
The EMA's human medicines committee has announced it has begun a rolling review of remdesivir for the treatment of COVID-19, to examine its safety and effectiveness.
The EMA's human medicines committee has adopted a positive opinion for eight medicines, recommending their marketing authorisation.
A summary of the CHMP meeting conclusions, including medicines recommended for approval and indication extension and several safety review findings.
The EMA has urged that the research community prioritise large randomised controlled studies for COVID-19 treatments and vaccines.
The EMA has recommended granting marketing authorisation to two medicines and extending the indications for three more following its latest meeting.
The EMA CHMP has revealed its suggestion to grant marketing authorisation to seven medicines after its most recent meeting.